Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Arcutis Biotherapeutics, Inc.
This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo. This study was prematurely terminated by the sponsor on 30-Jun-2021.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted